Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.
Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-d...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/aa4b88e29f75412e9bf812a4c6c27a2d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:aa4b88e29f75412e9bf812a4c6c27a2d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:aa4b88e29f75412e9bf812a4c6c27a2d2021-11-18T07:09:26ZMouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.1932-620310.1371/journal.pone.0042494https://doaj.org/article/aa4b88e29f75412e9bf812a4c6c27a2d2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22880004/?tool=EBIhttps://doaj.org/toc/1932-6203Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-deficient mouse skin carcinoma model to be similar to those of human cancers with TP53 mutations and associated with poor clinical outcomes. This report shows that much of the 682-gene signature of this murine skin carcinoma transcriptome is also present in breast and lung cancer mouse models in which p53 is inhibited. Further, we report validated gene-expression-based tests for predicting the clinical outcome of human breast and lung adenocarcinoma. It was found that human patients with cancer could be stratified based on the similarity of their transcriptome with the mouse skin carcinoma 682-gene signature. The results also provide new targets for the treatment of p53-defective tumours.Marta DueñasMirentxu SantosJuan F ArandaConcha BielzaAna B Martínez-CruzCorina LorzMiquel TaronEva M CiruelosJosé L Rodríguez-PeraltoMiguel MartínPedro LarrañagaJubrail DahabrehGeorge P StathopoulosRafael RosellJesús M ParamioRamón García-EscuderoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 8, p e42494 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Marta Dueñas Mirentxu Santos Juan F Aranda Concha Bielza Ana B Martínez-Cruz Corina Lorz Miquel Taron Eva M Ciruelos José L Rodríguez-Peralto Miguel Martín Pedro Larrañaga Jubrail Dahabreh George P Stathopoulos Rafael Rosell Jesús M Paramio Ramón García-Escudero Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| description |
Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-deficient mouse skin carcinoma model to be similar to those of human cancers with TP53 mutations and associated with poor clinical outcomes. This report shows that much of the 682-gene signature of this murine skin carcinoma transcriptome is also present in breast and lung cancer mouse models in which p53 is inhibited. Further, we report validated gene-expression-based tests for predicting the clinical outcome of human breast and lung adenocarcinoma. It was found that human patients with cancer could be stratified based on the similarity of their transcriptome with the mouse skin carcinoma 682-gene signature. The results also provide new targets for the treatment of p53-defective tumours. |
| format |
article |
| author |
Marta Dueñas Mirentxu Santos Juan F Aranda Concha Bielza Ana B Martínez-Cruz Corina Lorz Miquel Taron Eva M Ciruelos José L Rodríguez-Peralto Miguel Martín Pedro Larrañaga Jubrail Dahabreh George P Stathopoulos Rafael Rosell Jesús M Paramio Ramón García-Escudero |
| author_facet |
Marta Dueñas Mirentxu Santos Juan F Aranda Concha Bielza Ana B Martínez-Cruz Corina Lorz Miquel Taron Eva M Ciruelos José L Rodríguez-Peralto Miguel Martín Pedro Larrañaga Jubrail Dahabreh George P Stathopoulos Rafael Rosell Jesús M Paramio Ramón García-Escudero |
| author_sort |
Marta Dueñas |
| title |
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| title_short |
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| title_full |
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| title_fullStr |
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| title_full_unstemmed |
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| title_sort |
mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/aa4b88e29f75412e9bf812a4c6c27a2d |
| work_keys_str_mv |
AT martaduenas mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT mirentxusantos mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT juanfaranda mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT conchabielza mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT anabmartinezcruz mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT corinalorz mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT miqueltaron mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT evamciruelos mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT joselrodriguezperalto mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT miguelmartin mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT pedrolarranaga mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT jubraildahabreh mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT georgepstathopoulos mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT rafaelrosell mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT jesusmparamio mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes AT ramongarciaescudero mousep53deficientcancermodelsasplatformsforobtaininggenomicpredictorsofhumancancerclinicaloutcomes |
| _version_ |
1718423872824410112 |